Entertech VC continues to strengthen its deep technology investments in the healthcare sector. PhiTech, which focuses on the diagnosis of rare diseases by combining genomics and artificial intelligence technologies, has successfully completed its $2.4 million funding round. The round was led by Entertech VC, established through the collaboration between Entertech Istanbul Technopark and Yapı Kredi Portfolio Management.
With this investment round led by Entertech VC—founded in partnership between Entertech Istanbul Technopark and Yapı Kredi Portfolio Management—PhiTech increased its funding journey from an initial $500,000 to $2.4 million in its third round.
Founded in 2013 by Dr. Saliha Durmuş, Prof. Tunahan Çakır, and Prof. Erdoğan Sevilgen, PhiTech offers faster and more accurate diagnostic processes, particularly in rare diseases and oncology, through its proprietary G&M (Genomics & More) platform, which simultaneously analyzes DNA and RNA data. By moving beyond the limitations of conventional genetic testing approaches that rely solely on DNA data, this model strengthens clinical decision-making through multi-layered data analysis.
PhiTech’s technology provides critical infrastructure not only for diagnostics but also for patient management and drug development processes for hospitals, genetic diagnostic laboratories, and pharmaceutical companies. In doing so, it shortens the diagnostic journey for patients who may otherwise remain undiagnosed for years, while also contributing to the broader accessibility of precision medicine applications.
PhiTech will use its new investment to scale its multi-layered AI solutions developed for rare diseases in the market and to complete the R&D processes for its oncology-focused solutions. Within this scope, the company aims to expand its clinical use cases while accelerating its commercialization efforts.
Assoc. Prof. Dr. Muhammed Kasapoğlu, General Manager of Entertech Istanbul Technopark, commented on the investment as follows:
“One of the most critical fields shaping the new era of health technologies is the integration of genomic data and artificial intelligence. PhiTech’s multi-layered analytical approach holds strong potential to transform diagnostic processes, particularly in areas of high uncertainty such as rare diseases and cancer.
As a technopark rooted in the long-established medical faculties of Istanbul University and Istanbul University-Cerrahpaşa, we position deep specialization in healthcare as a strategic priority. We believe that this model—where academic expertise is integrated with entrepreneurship and investment mechanisms—plays a critical role in generating high value-added healthcare solutions.
As Entertech VC, we invest not only in ventures that develop technology, but also in those capable of transforming technology into globally impactful solutions. We believe our lead investment in PhiTech will contribute to the widespread adoption of precision medicine applications while strengthening Türkiye’s position in deep technology.”
Müge Peker, General Manager of Yapı Kredi Portfolio Management, also stated:
“As Yapı Kredi Portfolio Management, we prioritize standing alongside ventures that generate high added value and possess global competitiveness throughout their growth journeys. Through Entertech VC, we continue contributing to our country’s technology ecosystem by investing in ventures that develop innovative solutions, particularly in deep technology and healthcare. We believe this investment will support PhiTech’s global scaling journey by combining genomics and artificial intelligence.
With the strength we derive from our innovative financial vision and robust digital infrastructure, we position venture capital investments as a strategic growth area. In line with this approach, we aim to create sustainable value for our investors while advancing Türkiye’s entrepreneurial ecosystem by investing early in the technologies of the future.”
Through its systematic approach that prepares technology-based ventures for investment processes and connects them with the right investors, Entertech VC continues to support sustainable growth within the entrepreneurship ecosystem.